AvevoRx, a national, independent provider of specialty infusion pharmacy services, today announced significant growth in its in-home nursing program as the company continues investing in high-touch, ...

Graham Holdings Company ( GHC) Analyst/Investor Day December 9, 2025 1:00 PM EST ...

Miv-cel was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed. Grade 3/4 neutropenia, a known adverse event ...

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ...